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Abstract
Background: The CSF biomarkers tau and Ab42 can identify patients with AD, even during the preclinical stages. However,
previous studies on longitudinal changes of tau and Ab42 in individual patients with AD and elderly controls report
somewhat inconsistent results.
Methodology/Principal Findings: We investigated the levels of tau and Ab42 at baseline and after 1 year in 100 patients
with AD. In a second cohort of 45 AD patients we measured the CSF biomarkers at baseline and after 2 years. Moreover, in
34 healthy elderly controls the CSF biomarkers were followed for 4 years. The baseline levels of tau were increased with
.60% in AD patients compared to controls (p,0.001), while baseline Ab42 levels were decreased with .50% (p,0.001). In
the AD group followed for 2 years, tau increased with 16% compared to the baseline levels (p,0.05). However, the levels of
tau were stable over 4 years in the controls. The levels of Ab42 did not change significantly over time in any of the groups.
In the patients with AD, tau was moderately associated with worse cognitive performance already at baseline (p,0.05).
Conclusions/Significance: Tau and Ab42 in CSF seem to reflect the underlying disease state in both early and late stages of
AD. The slight increase in tau over time observed in the patients with AD is modest when compared to the relatively large
difference in absolute tau levels between AD patients and controls. Therefore, these markers maintain their usefulness as
state markers over time and might serve as surrogate markers for treatment efficacy in clinical trials.
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Introduction
Dementia is a growing health-economic issue worldwide.
Alzheimer’s disease (AD) accounts for most cases of dementia.
The onset of AD is insidious. The molecular pathology probably
starts 10–20 years before that patients with AD develop any
symptoms. The major pathological features in the brains of AD
patients are senile plaques, containing b-amyloid (Ab), and
neurofibrillary tangles with tau protein[1].
As novel therapies with possible disease-modifying effects are
under development, there is an urgent need for surrogate markers
to measure the potential biochemical effects of such therapies.
Cerebrospinal fluid (CSF) tau and Ab42 reflect the underlying
disease state and might serve as such surrogate markers[2].
However, for this purpose, the intra-individual variation of the
biomarker levels over time needs to be relatively small in order to
identify treatment effects.
CSF biomarkers might also be used in the diagnostic work up of
symptomatic AD patients, since the levels of tau are typically
increased, while the levels of Ab42 are decreased[2]. These
biomarkers can also predict progression to AD in subjects suffering
from mild cognitive impairment (MCI) with relatively high
accuracy[3,4,5]. There is evidence of changes of CSF tau and
Ab42 in the even earlier, pre-symptomatic phase of the AD[6,7].
In conclusion, the CSF levels of tau and Ab42 seem to be
substantially altered very early in the disease process of AD.
Numerous studies show that in groups of AD patients there is no
strong correlation between the severity of the disease stage and the
levels of tau and Ab42, indicating that the levels of the CSF
biomarkers do not change substantially over time in symptomatic
AD patients[2]. However, previous longitudinal studies of the
levels of tau in patients with AD show somewhat conflicting
results[8,9,10,11,12,13,14,15]. Some studies have shown that the
levels of CSF tau are stable over time[9,10,12], while others have
shown that tau levels are increased at follow-up[8,13]. The results
of studies on the stability of Ab42 in AD have also been
inconsistent - some studies have found no change over
time[10,11], while others have found longitudinal increments[8]
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conducted a longitudinal study in two rather large cohorts of
patients with AD. Lumbar puncture was performed at baseline
and after 1 year in 100 AD patients, while lumbar puncture was
performed at baseline and after 2 year in 45 AD patients.
Moreover, 34 healthy elderly controls underwent lumbar puncture
at baseline and after 4 years.
Methods
Subjects
The study sample was recruited at the memory disorder clinic,
Malmo ¨ University Hospital, Sweden. At baseline, physicians
specialized in cognitive disorders performed a thorough physical,
neurological and psychiatric examination, as well as a clinical
interview, of each patient. Computed tomography (CT) or
magnetic resonance imaging (MRI) of the brain was done, as well
as routine blood analyses and analysis of APOE genotype. The
patients were also evaluated with cognitive tests, including Mini-
mental State Examination (MMSE).
The patients with AD fulfilled the DSM-IIIR criteria of
dementia[16] and the criteria of probable AD defined by
NINCDS-ADRDA[17]. Their cognitive symptoms could not be
explained by other pathology.
The recruited 119 AD patients had undergone lumbar puncture
two times with an interval of 6–30 months. In 100 of these
patients, the time from baseline to the second lumbar puncture
was approximately one year (6–18 months) and they are
subsequently called the one-year AD cohort. In 45 AD patients
the interval between baseline and follow-up lumbar puncture was
two years (18–30 months) and they are subsequently called the
two-year AD cohort 2. In 26 of the AD patients there were follow-
up lumbar punctures performed at both one and two years and
they are included in both of the cohorts. All patients were during
the follow-up period continuously tested with cognitive tests
including MMSE.
For the age-matched control population the inclusion criteria
were: (i) absence of memory complaints or any other cognitive
symptoms, (ii) preservation of general cognitive functioning, and
(iii) no active neurological or psychiatric disease. At baseline, 36
controls with MMSE scores over 27 were included. The controls
were followed clinically and evaluated with MMSE after 4 years,
in order to rule out development of cognitive decline. At follow-up,
two patients exhibited significant cognitive dysfunction and were
therefore excluded. The remaining 34 controls had MMSE scores
$27 at follow- up. Lumbar puncture was performed at baseline
and after 4 years (range 3.7–4.2).
Ethics Statement
All patients gave written informed consent to participate in the
study. The study was conducted according to the provisions of the
Helsinki Declaration and approved by the ethics committee of
Lund University, Sweden.
Analyses of levels of tau and Ab42
The CSF samples were collected by lumbar puncture. The first
12 mL of CSF was collected in a polypropylene tube, directly
transported to the local laboratory for centrifugation at 20006g at
+4uC for 10 min. The supernatant was pipetted off, gently mixed
to avoid potential gradient effects, and aliquoted in 1 mL portions
in polypropylene tubes that were stored at 280uC pending
biochemical analyses, without being thawed and re-frozen.
In the AD patients, CSF total tau (T-tau) concentration was
determined using a sandwich ELISA (Innotest hTAU-Ag,
Innogenetics, Gent, Belgium) specifically constructed to measure
all tau isoforms irrespectively of phosphorylation status, as
previously described[18]. CSF Ab1-42 levels were determined
using a sandwich ELISA (InnotestH ß- amyloid (1–42),
Innogenetics, Gent, Belgium), specifically constructed to measure
Ab containing both the first and 42
nd amino acid, as previously
described[11]. In the 1-year AD cohort repeated measurement
of CSF tau and CSF Ab42 were done in 100 and 97 subjects,
respectively. In the 2-year AD cohort repeated measurement of
CSF tau and Ab42 were done in 45 and 42 subjects,
respectively.
In the cognitively normal controls, the concentrations of tau and
Ab42 in CSF was determined with xMAP technology using the
INNO-BIA AlzBio3 kit (Innogenetics, Ghent, Belgium)[4]. Results
from the Luminex xMAP system were converted to ELISA levels
based on previously published conversion factors[19].
Statistical analyses
To compare continuous baseline data between the cohorts, non-
parametric Kruskal-Wallis ANOVA was performed, followed by
Mann-Whitney U-test. Pearson’s x
2 test was used for dichotomous
variables. Wilcoxon signed-rank test was used to compare baseline
and follow-up data in the cohorts. Spearman’s correlation
coefficient was used for correlation analyses. The statistical
analyses were accomplished with SPSS for Windows, version 16.0.
Results
Baseline CSF levels of tau and Ab42
The baseline demographic variables of the two AD cohorts and
the age-matched controls are given in table 1. Both the baseline
CSF levels of tau in the 1-year AD cohort (6936301 ng/l) and in
the 2-year AD cohort (6636308 ng/l) were significantly elevated
with 61–68%, when compared to the baseline levels in the control
group (4126232 ng/l; P,0.001) (table 2). In contrast, the baseline
CSF levels of Ab42 in the 1-year AD cohort (2756103 ng/l) and
in the 2-year AD cohort (2886103 ng/l) were significantly
reduced with 56–58%, when compared to the baseline levels in
the control group (6596179 ng/l; P,0.001) (table 2). Further-
more, the above described alterations of tau and Ab42 were highly
significant both in AD patients with low and high scores on
MMSE at baseline, when compared to the healthy controls (data
not shown).
Longitudinal changes of the CSF levels of tau and Ab42
in the AD patients
The levels of CSF tau were non-significantly higher at follow-
up compared to the baseline levels in the 1-year AD cohort
(P.0.05; table 2, figure 1). Also the levels of CSF Ab42 were
non-significantly higher at follow-up in this group (P.0.05;
table 2, figure 1). In the 2-year AD cohort, the levels of CSF tau
were significantly increased with 15.8% at follow-up, when
compared to the baseline levels (p=0.03; table 2, figure 1).
Furthermore, the CSF levels of Ab42 were non-significantly
increased at follow-up compared to baseline in this group
(P.0.05; table 2, figure 1).
Longitudinal changes of the CSF levels of tau and Ab42
in the controls
At follow-up, the CSF levels of tau were slightly and non-
significantly lower compared to the baseline levels (table 2,
figure 1). A modest and non-significant decrease of Ab42 was also
observed during follow-up (table 2, figure 1).
Stability of AD Biomarkers
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and cognitive performance
In the 1-year AD cohort, high levels of CSF tau at baseline, but
not Ab42, correlated moderately to poor baseline performance on
the cognitive test MMSE (rs=20.22, p,0.05). In the 2-year AD
cohort, similar correlations between the baseline levels of tau, but
not Ab42, and MMSE performance (rs=20.40, p,0.01) were
found. However, baseline levels of tau or Ab42 did not correlate
with cognitive deterioration over time as measured with repeated
MMSE during the clinical follow-up (p.0.05). Moreover, changes
in tau or Ab42 levels over time did not correlate with the rate of
cognitive deterioration (p.0.05).
Discussion
We found that the baseline levels of CSF tau were increased
with around 60% in AD patients compared to controls, while
baseline CSF Ab42 levels were decreased with more than 50%. In
AD patients, tau increased with 16% over two years and CSF tau
was moderately associated with worse cognitive performance
already at baseline. However, the levels of tau were stable over 4
years in the controls. The levels of Ab42 did not change
significantly over time in any of the groups and did not correlate
with baseline cognitive performance.
Biomarkers for neurodegenerative disorders can be divided into
markers of disease state and markers of disease stage or rate[20].
Markers of disease state, usually called diagnostic biomarkers,
facilitate detection of a certain biological disease in populations of
individuals with similar symptoms (e.g. memory impairment)
caused by different conditions. A disease state marker should
ideally exhibit a high diagnostic accuracy over the entire course of
the disease process. Both CSF tau and Ab42 fulfill the
requirements for disease state markers of AD, because these
biomarkers exhibit reasonably high specificity and sensitivity for
both early and late stages of AD[2]. The results of the present
study suggest that CSF Ab42 is not a marker of disease stage or
rate, since the levels are stable over time in individual patients with
AD and do not correlate with cognitive function. Similarly,
previous studies show that the amyloid load in the brain of AD
patients, as assessed with repeated positron emission tomography
(PIB-PET) measurements, keeps stable over time despite cognitive
decline[21]. It might be that Ab42 levels in both the CSF and the
brain are altered during the very early preclinical stages of AD and
are thereafter relatively stable during the symptomatic course of
the disease.
The present study suggests that tau levels in CSF increase
slightly over time. In agreement, Stefani and collaborators have
found that CSF tau levels are associated with the disease stage of
AD[22], a finding supported by the moderate correlation between
cognitive performance and CSF tau found in the present study.
Therefore, it might be that CSF tau, in addition to being a robust
disease state marker, to some degree reflects the disease stage.
Table 1. Demographic characteristics of the AD patients and the age-matched controls at baseline and follow-up.
Controls, n=34 1-year AD cohort, n=100 2-year AD cohort, n=45
Age, years 7268.3 7467.2 7367.1
Sex, M/F 10/24 36/64 22/23
APOE e4 carrier, % 26.5 67.7
a 75.6
a
Follow-up time, y 3.860.1 1.260.2 2.160.2
MMSE, baseline (0–30 p) 29.361.0 21.864.8
a 23.464.4
a
MMSE, follow-up (0–30 p) 28.761.2 20.465.6 20.266.9
Values are means6SD, except as noted otherwise.
ap,0.001 vs Controls.
Abbreviations: 1-year AD cohort, AD patients with approximately one year between baseline and follow-up lumbar puncture; 2-year AD cohort, AD patients with
approximately two years between baseline and follow-up lumbar puncture; Controls, healthy controls followed for 4 years; APOE e4 carrier, at least one apolipoprotein E
e4 allele; MMSE, Mini-Mental State Examination.
doi:10.1371/journal.pone.0006294.t001
Table 2. Baseline and follow-up levels of CSF tau and Ab42 in the AD patients and age-matched controls.
Controls, n=34 1-year AD cohort, n=100 2-year AD cohort, n=45
Baseline Tau, ng/L 4126232 6936301
a 6636308
a
Follow-up Tau, ng/L 3996194 7316402 7686528
b
Longitudinal difference, Tau, % 23.2 +5.5 +15.8
Baseline Ab42, ng/L 6596179 2756103
a 2886103
a
Follow-up Ab42, ng/L 6516168 2966132 3216137
Longitudinal difference, Ab42, % 21.2 +7.6 +11.5
Values are means6SD except if noted otherwise.
ap,0.001 vs Controls.
bp,0.05 vs baseline.
Abbreviations: CSF, cerebrospinal fluid; 1-year AD cohort, subjects with Alzheimer’s disease with an interval between baseline and follow-up lumbar puncture of
approximately one year; 2-year AD cohort, subjects with Alzheimer’s disease with an interval between baseline and follow-up lumbar puncture of approximately two
years. Controls, healthy controls followed for 4 years.
doi:10.1371/journal.pone.0006294.t002
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These observations are supported by neuropathological studies
showing that tau-containing neurofibrillary tangles, but not
amyloid plaques, are associated with the cognitive function of
AD patients[23]. However, other methods such as cognitive tests
or measures of brain atrophy or cerebral blood flow are likely to
prove to be more valuable as disease stage markers of
AD[24,25,26], and CSF biomarkers should primarily be used as
diagnostic markers detecting the underlying disease state[2].
Therefore, different methods should be combined when defining
the disease state and stage of individual patients with cognitive
dysfunction.
CSF biomarkers, such as tau and Ab42, could possibly also be
used as surrogate markers in clinical therapeutic AD trials. Surrogate
biomarkers should be involved in the early pathophysiologic
cascade and they ought to inform on biological interactions with
the molecular target of the drug in humans [20]. Future disease-
modifying therapies against AD may halt the degenerative process,
but are not expected to have direct symptomatic effects. As a result
no short-term cognitive improvements are expected in such trials.
Therefore, large patient populations and extensive treatment
periods will be required to identify treatment effects on clinical
parameters. Data from smaller pilot investigations, using biomark-
ers as endpoint to determine whether a certain drug is reaching
and acting on its biological target in patients with AD, would be
very valuable when making a go/no-go decision for an expensive
clinical trial with clinical improvement as the endpoint[2].
However, the markers used as surrogate markers in such trials
must have a low intra-individual variation over time. The present
study confirms previous investigations that the changes of CSF tau
and Ab42 is very modest over time in individual patients with
AD[8,9,10,11,12,13,14], which might indicate that these CSF
biomarkers may serve as sensitive tools to identify and monitor
even minor biochemical changes induced by treatments that are
directed against these targets, such as Ab immunotherapy. For
example, recently Lannfelt and colleagues found that PBT2 (a
metal-protein attenuating compound) reduced the levels of Ab42
in CSF, but not plasma, of patients with AD, indicating that the
drug had a central effect on Ab metabolism[27].
In conclusion, CSF tau and Ab42 seem to reflect the underlying
disease state in both early and late stages of AD. The slight
increase in tau over time observed in patients with AD is modest
when compared to the relatively large difference in absolute tau
levels observed between AD patients and controls, indicating that
tau and Ab42 do not primarily reflect the progression of the
disease over time. Therefore, these markers might serve as
surrogate markers for treatment efficacy in clinical trials.
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